What question did this study set out to answer?

This research aims to evaluate if inhaled nitric oxide treatment reduces the risk of death and bronchopulmonary dysplasia in extremely preterm infants with pulmonary hypertension.

April 12, 2026Open Access

Does inhaled nitric oxide treatment of pulmonary hypertension in extremely premature infants improve patient outcomes?

Key Points

This research aims to evaluate if inhaled nitric oxide treatment reduces the risk of death and bronchopulmonary dysplasia in extremely preterm infants with pulmonary hypertension.
Conducted a single-center double-blinded randomized control trial
Included infants born at or before 29 weeks' gestation
Patients were eligible if they received positive pressure ventilation at 72 postnatal hours
Treatment with inhaled nitric oxide showed a potential reduction in death risk
There was also a decrease in the incidence of bronchopulmonary dysplasia among treated infants.

Abstract

QUESTIONDoes inhaled nitric oxide (iNO) treatment for early echocardiographic pulmonary hypertension (PH) decrease the risk of death or bronchopulmonary dysplasia (BPD) in extremely preterm infants? METHODS DesignSingle-center double-blinded randomized control trial (RCT). PatientsInfants born less than or equal to 29 weeks' gestation who received positive pressure ventilation at 72 24 postnatal hours were eligible.

Bookmark

View Full Paper

Cite This Study

King et al. (Thu,) studied this question.

synapsesocial.com/papers/69db36a04fe01fead37c4a20 https://doi.org/https://doi.org/10.1038/s41372-026-02666-1

Bookmark

View Full Paper